Expertise in
15
conditions

Neil E. Fleshner

700 University Avenue, 
Toronto, ON, CA 
Expertise in
15
conditions
700 University Avenue, 
Toronto, ON, CA 

Overview

Neil Fleshner practices practicing medicine in Toronto, Canada.

Mr. Fleshner is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Prostatectomy, and Cystectomy.

He is actively involved in clinical research, co-authoring 570 peer reviewed articles and participating in 13 clinical trials.

Gender

Male

Locations

700 University Avenue, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study
Enrollment Status: Terminated
Publish Date: July 29, 2026
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
Hypoxia and Stem Cell Content as Aggression Factors in Prostate Cancer
Hypoxia and Stem Cell Content as Aggression Factors in Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 23, 2026
Intervention Type: Drug
Study Phase: Not Applicable
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is Indicated
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is Indicated
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Prednisone, Leuprolide, Cabazitaxel, Peg-filgrastim
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study
Enrollment Status: Unknown
Publish Date: January 24, 2024
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Unknown
Publish Date: January 24, 2024
Intervention Type: Drug
Study Drugs: Dexamethasone, Radium-223 Dichloride
Study Phase: Phase 4
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Drugs: GSK525762, Abiraterone, Enzalutamide, Prednisone
Study Phase: Phase 1
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Device, Procedure
Study Phase: Not Applicable
A Randomized, Double Blind, Trial of Metformin and Atorvastatin in Delaying Androgen Deprivation Therapy Among Men With Rising PSA Following Radical Prostatectomy or Radiotherapy: The LIGAND (LIpitor and biGuanide to Androgen Delay) Trial
A Randomized, Double Blind, Trial of Metformin and Atorvastatin in Delaying Androgen Deprivation Therapy Among Men With Rising PSA Following Radical Prostatectomy or Radiotherapy: The LIGAND (LIpitor and biGuanide to Androgen Delay) Trial
Enrollment Status: Withdrawn
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial
An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial
Enrollment Status: Completed
Publish Date: January 13, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

570 Total Publications

Oncological Outcomes of Nonmuscle-Invasive Bladder Cancer in Patients Aged 45 Years and Younger: A Retrospective Matched Cohort Study.
Oncological Outcomes of Nonmuscle-Invasive Bladder Cancer in Patients Aged 45 Years and Younger: A Retrospective Matched Cohort Study.
Journal: The Journal of urology
Published: June 24, 2026

Frequently Asked Questions about Neil E. Fleshner

Is Neil E. Fleshner a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Neil E. Fleshner is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Neil E. Fleshner participate in research or clinical trials?

Yes. Neil E. Fleshner has published 570 articles and abstracts on conditions like Prostate Cancer. You can view a list of Neil E. Fleshner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fleshner's expertise for a condition
ConditionClose
View All 25 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile